본문 바로가기
KERD
논문KCI 등재

Diagnosis and Management of High Risk Group for Gastric Cancer

김나영|윤혁
거트앤리버 소화기연관학회협의회|2015.01|Gut and Liver|제9권 제1호|pp. 5-17

2

조회

0

다운로드

10

인용

0

참고문헌

키워드

Risk factorsRisk managementStomach neoplasms

초록

Gastric cancer is associated with high morbidity and mortality worldwide. To reduce the socioeconomic burden related to gastric cancer, it is very important to identify and manage high risk group for gastric cancer. In this review, we describe the general risk factors for gastric cancer and define high risk group for gastric cancer. We discuss strategies for the effective management of patients for the prevention and early detection of gastric cancer. Atrophic gastritis (AG) and intestinal metaplasia (IM) are the most significant risk factors for gastric cancer. Therefore, the accurate selection of individuals with AG and IM may be a key strategy for the prevention and/or early detection of gastric cancer. Although endoscopic evaluation using enhanced technologies such as narrow band imaging-magnification, the serum pepsinogen test, Helicobacter pylori serology, and trefoil factor 3 have been evaluated, a gold standard method to accurately select individuals with AG and IM has not emerged. In terms of managing patients at high risk of gastric cancer, it remains uncertain whether H. pylori eradication reverses and/or prevents the progression of AG and IM. Although endoscopic surveillance in high risk patients is expected to be beneficial, further prospective studies in large populations are needed to determine the optimal surveillance interval.

Abstract

Gastric cancer is associated with high morbidity and mortality worldwide. To reduce the socioeconomic burden related to gastric cancer, it is very important to identify and manage high risk group for gastric cancer. In this review, we describe the general risk factors for gastric cancer and define high risk group for gastric cancer. We discuss strategies for the effective management of patients for the prevention and early detection of gastric cancer. Atrophic gastritis (AG) and intestinal metaplasia (IM) are the most significant risk factors for gastric cancer. Therefore, the accurate selection of individuals with AG and IM may be a key strategy for the prevention and/or early detection of gastric cancer. Although endoscopic evaluation using enhanced technologies such as narrow band imaging-magnification, the serum pepsinogen test, Helicobacter pylori serology, and trefoil factor 3 have been evaluated, a gold standard method to accurately select individuals with AG and IM has not emerged. In terms of managing patients at high risk of gastric cancer, it remains uncertain whether H. pylori eradication reverses and/or prevents the progression of AG and IM. Although endoscopic surveillance in high risk patients is expected to be beneficial, further prospective studies in large populations are needed to determine the optimal surveillance interval.

참고문헌 (111)

  1. Ferlay J, "Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008", Int J Cancer, 127, pp.2893~2917 (2010)
  2. Correa P, "Human gastric carcinogenesis: a multistep and multifactorial process: First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention", Cancer Res, 52, pp.6735~6740 (1992)
  3. de Vries AC, "Epidemiology of premalignant gastric lesions:implications for the development of screening and surveillance strategies", Helicobacter, 12(2), pp.22~31 (2007)
  4. Yoon H, "Helicobacter pylori-negative gastric cancer in South Korea: incidence and clinicopathologic characteristics", Helicobacter, 16, pp.382~388 (2011)
  5. Kato S, "Helicobacter pylori infection-negative gastric cancer in Japanese hospital patients: incidence and pathological characteristics", Cancer Sci, 98, pp.790~794 (2007)
  6. Huang JQ, "Meta-analysis of the relationship between Helicobacter pylori seropositivity and gastric cancer", Gastroenterology, 114, pp.1169~1179 (1998)
  7. Xue FB, "Association of H. pylori infection with gastric carcinoma: a meta analysis", World J Gastroenterol, 7, pp.801~804 (2001)
  8. Wang XQ, "Review of salt consumption and stomach cancer risk: epidemiological and biological evidence", World J Gastroenterol, 15, pp.2204~2213 (2009)
  9. Fock KM, "Asia-Pacific consensus guidelines on gastric cancer prevention", J Gastroenterol Hepatol, 23, pp.351~365 (2008)
  10. D’Elia L, "Habitual salt intake and risk of gastric cancer: a meta-analysis of prospective studies", Clin Nutr, 31, pp.489~498 (2012)
  11. Dias-Neto M, "Salt intake and risk of gastric intestinal metaplasia: systematic review and metaanalysis", Nutr Cancer, 62, pp.133~147 (2010)
  12. Ladeiras-Lopes R, "Smoking and gastric cancer: systematic review and meta-analysis of cohort studies", Cancer Causes Control, 19, pp.689~701 (2008)
  13. La Torre G, "Smoking status and gastric cancer risk: an updated meta-analysis of case-control studies published in the past ten years", Tumori, 95, pp.13~22 (2009)
  14. Tramacere I, "A meta-analysis on alcohol drinking and gastric cancer risk", Ann Oncol, 23, pp.28~36 (2012)
  15. Jarl J, "Time characteristics of the effect of alcohol cessation on the risk of stomach cancer: a meta-analysis", BMC Public Health, 13, pp.600~ (2013)
  16. Shin CM, "Association between alcohol intake and risk for gastric cancer with regard to ALDH2 genotype in the Korean population", Int J Epidemiol, 40, pp.1047~1055 (2011)
  17. Enomoto N, "Acetaldehyde metabolism in different aldehyde dehydrogenase-2 genotypes", Alcohol Clin Exp Res, 15, pp.141~144 (1991)
  18. Lewis SJ, "Alcohol, ALDH2, and esophageal cancer: a meta-analysis which illustrates the potentials and limitations of a Mendelian randomization approach", Cancer Epidemiol Biomarkers Prev, 14, pp.1967~1971 (2005)
  19. Correa P, "A model for gastric cancer epidemiology", Lancet, 2, pp.58~60 (1975)
  20. Sierra R, "Exposure to N-nitrosamines and other risk factors for gastric cancer in Costa Rican children", IARC Sci Publ, 105, pp.162~167 (1991)
  21. Møller ME, "A possible role of the dietary fibre product, wheat bran, as a nitrite scavenger", Food Chem Toxicol, 26, pp.841~845 (1988)
  22. Zhang Z, "Dietary fiber intake reduces risk for gastric cancer: a meta-analysis", Gastroenterology, 145, pp.113~120 (2013)
  23. Barker DJ, "Poor housing in childhood and high rates of stomach cancer in England and Wales", Br J Cancer, 61, pp.575~578 (1990)
  24. Roder DM, "The epidemiology of gastric cancer", Gastric Cancer, 5(1), pp.5~11 (2002)
  25. Shin CM, "Stomach cancer risk in gastric cancer relatives: interaction between Helicobacter pylori infection and family history of gastric cancer for the risk of stomach cancer", J Clin Gastroenterol, 44, pp.e34~e39 (2010)
  26. Brenner H, "Individual and joint contribution of family history and Helicobacter pylori infection to the risk of gastric carcinoma", Cancer, 88, pp.274~279 (2000)
  27. Rokkas T, "Helicobacter pylori infection and gastric histology in first-degree relatives of gastric cancer patients: a meta-analysis", Eur J Gastroenterol Hepatol, 22, pp.1128~1133 (2010)
  28. Chen Y, "Body mass index and risk of gastric cancer: a meta-analysis of a population with more than ten million from 24 prospective studies", Cancer Epidemiol Biomarkers Prev, 22, pp.1395~1408 (2013)
  29. de Vries AC, "Gastric cancer risk in patients with premalignant gastric lesions: a nationwide cohort study in the Netherlands", Gastroenterology, 134, pp.945~952 (2008)
  30. Tatsuta M, "Fundal atrophic gastritis as a risk factor for gastric cancer", Int J Cancer, 53, pp.70~74 (1993)
  31. Leung WK, "Review article: intestinal metaplasia and gastric carcinogenesis", Aliment Pharmacol Ther, 16, pp.1209~1216 (2002)
  32. You WC, "Evolution of precancerous lesions in a rural Chinese population at high risk of gastric cancer", Int J Cancer, 83, pp.615~619 (1999)
  33. Correa P, "Pathology of gastric intestinal metaplasia: clinical implications", Am J Gastroenterol, 105, pp.493~498 (2010)
  34. Filipe MI, "Intestinal metaplasia types and the risk of gastric cancer: a cohort study in Slovenia", Int J Cancer, 57, pp.324~329 (1994)
  35. Rokkas T, "Detection of an increased incidence of early gastric cancer in patients with intestinal metaplasia type III who are closely followed up", Gut, 32, pp.1110~1113 (1991)
  36. Conchillo JM, "Is type III intestinal metaplasia an obligatory precancerous lesion in intestinal-type gastric carcinoma?", Eur J Cancer Prev, 10, pp.307~312 (2001)
  37. Kang KP, "Role of intestinal metaplasia subtyping in the risk of gastric cancer in Korea", J Gastroenterol Hepatol, 24, pp.140~148 (2009)
  38. Dinis-Ribeiro M, "Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED)", Endoscopy, 44, pp.74~94 (2012)
  39. González CA, "Utility of subtyping intestinal metaplasia as marker of gastric cancer risk: a review of the evidence", Int J Cancer, 133, pp.1023~1032 (2013)
  40. Cassaro M, "Topographic patterns of intestinal metaplasia and gastric cancer", Am J Gastroenterol, 95, pp.1431~1438 (2000)
  41. Silberg DG, "Cdx1 and cdx2 expression during intestinal development", Gastroenterology, 119, pp.961~971 (2000)
  42. Almeida R, "Expression of intestinespecific transcription factors, CDX1 and CDX2, in intestinal metaplasia and gastric carcinomas", J Pathol, 199, pp.36~40 (2003)
  43. 강정묵, "CDX1 and CDX2 Expression in Intestinal Metaplasia, Dysplasia and Gastric Cancer", Journal of Korean Medical Science, 26(5), pp.647~653 (2011), 대한의학회
  44. Byoung Hwan Lee, "The Role of CDX2 in Intestinal Metaplasia Evaluated Using Immunohistochemistry", Gut and Liver, 6(1), pp.71~77 (2012), 거트앤리버 발행위원회
  45. Eshmuratov A, "The correlation of endoscopic and histological diagnosis of gastric atrophy", Dig Dis Sci, 55, pp.1364~1375 (2010)
  46. 임지환, "Correlation between Endoscopic and Histological Diagnoses of Gastric Intestinal Metaplasia", Gut and Liver, 7(1), pp.41~45 (2013), 거트앤리버 발행위원회
  47. Hirata I, "Usefulness of magnifying narrow-band imaging endoscopy for the diagnosis of gastric and colorectal lesions", Digestion, 85, pp.74~79 (2012)
  48. Uedo N, "A new method of diagnosing gastric intestinal metaplasia: narrow-band imaging with magnifying endoscopy", Endoscopy, 38, pp.819~824 (2006)
  49. Rerknimitr R, "Non-sequential narrow band imaging for targeted biopsy and monitoring of gastric intestinal metaplasia", World J Gastroenterol, 17, pp.1336~1342 (2011)
  50. Capelle LG, "Narrow band imaging for the detection of gastric intestinal metaplasia and dysplasia during surveillance endoscopy", Dig Dis Sci, 55, pp.3442~3448 (2010)
  51. Rugge M, "Gastritis staging in clinical practice: the OLGA staging system", Gut, 56, pp.631~636 (2007)
  52. Rugge M, "Gastritis OLGA-staging and gastric cancer risk: a twelve-year clinico-pathological followup study", Aliment Pharmacol Ther, 31, pp.1104~1111 (2010)
  53. Capelle LG, "The staging of gastritis with the OLGA system by using intestinal metaplasia as an accurate alternative for atrophic gastritis", Gastrointest Endosc, 71, pp.1150~1158 (2010)
  54. den Hoed CM, "Follow-up of premalignant lesions in patients at risk for progression to gastric cancer", Endoscopy, 45, pp.249~256 (2013)
  55. Cho SJ, "Staging of intestinal-and diffuse-type gastric cancers with the OLGA and OLGIM staging systems", Aliment Pharmacol Ther, 38, pp.1292~1302 (2013)
  56. Kuipers EJ, "Review article: relationship between Helicobacter pylori, atrophic gastritis and gastric cancer", Aliment Pharmacol Ther, 12(1), pp.25~36 (1998)
  57. 김나영, "The Role of Serum Pepsinogen in the Detection of Gastric Cancer", Gut and Liver, 4(3), pp.307~319 (2010), 거트앤리버 발행위원회
  58. Kitahara F, "Accuracy of screening for gastric cancer using serum pepsinogen concentrations", Gut, 44, pp.693~697 (1999)
  59. Yanaoka K, "Cancer high-risk subjects identified by serum pepsinogen tests: outcomes after 10-year follow-up in asymptomatic middle-aged males", Cancer Epidemiol Biomarkers Prev, 17, pp.838~845 (2008)
  60. Dinis-Ribeiro M, "Meta-analysis on the validity of pepsinogen test for gastric carcinoma, dysplasia or chronic atrophic gastritis screening", J Med Screen, 11, pp.141~147 (2004)
  61. Miki K, "Long-term results of gastric cancer screening using the serum pepsinogen test method among an asymptomatic middle-aged Japanese population", Dig Endosc, 21, pp.78~81 (2009)
  62. Kang JM, "The role of serum pepsinogen and gastrin test for the detection of gastric cancer in Korea", Helicobacter, 13, pp.146~156 (2008)
  63. Watabe H, "Predicting the development of gastric cancer from combining Helicobacter pylori antibodies and serum pepsinogen status: a prospective endoscopic cohort study", Gut, 54, pp.764~768 (2005)
  64. Yanaoka K, "Risk of gastric cancer in asymptomatic, middle-aged Japanese subjects based on serum pepsinogen and Helicobacter pylori antibody levels", Int J Cancer, 123, pp.917~926 (2008)
  65. Ohata H, "Progression of chronic atrophic gastritis associated with Helicobacter pylori infection increases risk of gastric cancer", Int J Cancer, 109, pp.138~143 (2004)
  66. Yoshida T, "Cancer development based on chronic active gastritis and resulting gastric atrophy as assessed by serum levels of pepsinogen and Helicobacter pylori antibody titer", Int J Cancer, 134, pp.1445~1457 (2014)
  67. Perry JK, "Are trefoil factors oncogenic?", Trends Endocrinol Metab, 19, pp.74~81 (2008)
  68. Dhar DK, "Expression of trefoil factor family members correlates with patient prognosis and neoangiogenesis", Clin Cancer Res, 11, pp.6472~6478 (2005)
  69. Peterson AJ, "Helicobacter pylori infection promotes methylation and silencing of trefoil factor 2, leading to gastric tumor development in mice and humans", Gastroenterology, 139, pp.2005~2017 (2010)
  70. Wong WM, "Trefoil peptides", Gut, 44, pp.890~895 (1999)
  71. Kjellev S, "The trefoil factor family: small peptides with multiple functionalities", Cell Mol Life Sci, 66, pp.1350~1369 (2009)
  72. Ribieras S, "The pS2", TFF1 trefoil factor, from basic research to clinical applications, 1998, pp.1378, F61~F77
  73. Plaut AG, "Trefoil peptides in the defense of the gastrointestinal tract", N Engl J Med, 336, pp.506~507 (1997)
  74. Kaise M, "The combination of serum trefoil factor 3 and pepsinogen testing is a valid non-endoscopic biomarker for predicting the presence of gastric cancer: a new marker for gastric cancer risk", J Gastroenterol, 46, pp.736~745 (2011)
  75. Aikou S, "Tests for serum levels of trefoil factor family proteins can improve gastric cancer screening", Gastroenterology, 141, pp.837~845 (2011)
  76. Kaise M, "Influence of Helicobacter pylori status and eradication on the serum levels of trefoil factors and pepsinogen test: serum trefoil factor 3 is a stable biomarker", Gastric Cancer, 16, pp.329~337 (2013)
  77. González CA, "Carcinogenesis, prevention and early detection of gastric cancer: where we are and where we should go", Int J Cancer, 130, pp.745~753 (2012)
  78. Malfertheiner P, "Management of Helicobacter pylori infection: the Maastricht IV", Florence Consensus Report, 2012, pp.61, 646~664
  79. Uemura N, "Helicobacter pylori infection and the development of gastric cancer", N Engl J Med, 345, pp.784~789 (2001)
  80. Wong BC, "Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial", JAMA, 291, pp.187~194 (2004)
  81. Fuccio L, "Meta-analysis: can Helicobacter pylori eradication treatment reduce the risk for gastric cancer?", Ann Intern Med, 151, pp.121~128 (2009)
  82. Lee YC, "The benefit of mass eradication of Helicobacter pylori infection: a community-based study of gastric cancer prevention", Gut, 62, pp.676~682 (2013)
  83. Liu WZ, "Fourth Chinese National Consensus Report on the management of Helicobacter pylori infection", J Dig Dis, 14, pp.211~221 (2013)
  84. Asaka M, "Guidelines for the management of Helicobacter pylori infection in Japan", Helicobacter, 15, pp.1~20 (2010)
  85. 김상균, "한국인 헬리코박터 파일로리 감염의 진단과 치료 임상 진료지침 개정안 2013", 대한소화기학회지, 62(1), pp.3~26 (2013), 대한소화기학회
  86. Mera R, "Long term follow up of patients treated for Helicobacter pylori infection", Gut, 54, pp.1536~1540 (2005)
  87. You WC, "Randomized double-blind factorial trial of three treatments to reduce the prevalence of precancerous gastric lesions", J Natl Cancer Inst, 98, pp.974~983 (2006)
  88. Leung WK, "Factors predicting progression of gastric intestinal metaplasia: results of a randomised trial on Helicobacter pylori eradication", Gut, 53, pp.1244~1249 (2004)
  89. Rokkas T, "The long-term impact of Helicobacter pylori eradication on gastric histology: a systematic review and meta-analysis", Helicobacter, 12(2), pp.32~38 (2007)
  90. Asaka M, "A new approach for elimination of gastric cancer deaths in Japan", Int J Cancer, 132, pp.1272~1276 (2013)
  91. Uemura N, "Effect of Helicobacter pylori eradication on subsequent development of cancer after endoscopic resection of early gastric cancer", Cancer Epidemiol Biomarkers Prev, 6, pp.639~642 (1997)
  92. Fukase K, "Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial", Lancet, 372, pp.392~397 (2008)
  93. Maehata Y, "Long-term effect of Helicobacter pylori eradication on the development of metachronous gastric cancer after endoscopic resection of early gastric cancer", Gastrointest Endosc, 75, pp.39~46 (2012)
  94. Choi J, "Eradication of Helicobacter pylori after endoscopic resection of gastric tumors does not reduce incidence of metachronous gastric carcinoma", Clin Gastroenterol Hepatol, 12, pp.793~800 (2014)
  95. Hamashima C, "The Japanese guidelines for gastric cancer screening", Jpn J Clin Oncol, 38, pp.259~267 (2008)
  96. "National cancer control programs in Korea", J Korean Med Sci, 22, pp.S3~S4 (2007)
  97. Liu CY, "Multistate and multifactorial progression of gastric cancer: results from community-based mass screening for gastric cancer", J Med Screen, 13(1), pp.S2~S5 (2006)
  98. Lee H, "Survival outcome associated with the screening interval for gastric cancer in Korea", Digestion, 84, pp.142~148 (2011)
  99. Nam SY, "Effect of repeated endoscopic screening on the incidence and treatment of gastric cancer in health screenees", Eur J Gastroenterol Hepatol, 21, pp.855~860 (2009)
  100. Gates TJ, "Screening for cancer: evaluating the evidence", Am Fam Physician, 63, pp.513~522 (2001)
  101. Hosokawa O, "Decreased death from gastric cancer by endoscopic screening: association with a population-based cancer registry", Scand J Gastroenterol, 43, pp.1112~1115 (2008)
  102. Riecken B, "No impact of repeated endoscopic screens on gastric cancer mortality in a prospectively followed Chinese population at high risk", Prev Med, 34, pp.22~28 (2002)
  103. Mori Y, "Effect of periodic endoscopy for gastric cancer on early detection and improvement of survival", Gastric Cancer, 4, pp.132~136 (2001)
  104. Dan YY, "Endoscopic screening for gastric cancer", Clin Gastroenterol Hepatol, 4, pp.709~716 (2006)
  105. Yoon H, "Effect of endoscopic screening at 1-year intervals on the clinicopathologic characteristics and treatment of gastric cancer in South Korea", J Gastroenterol Hepatol, 27, pp.928~934 (2012)
  106. Chung SJ, "Effect of annual endoscopic screening on clinicopathologic characteristics and treatment modality of gastric cancer in a high-incidence region of Korea", Int J Cancer, 131, pp.2376~2384 (2012)
  107. Zullo A, "Follow-up of intestinal metaplasia in the stomach: when, how and why", World J Gastrointest Oncol, 4, pp.30~36 (2012)
  108. Whiting JL, "The long term results of endoscopic surveillance of premalignant gastric lesions", Gut, 50, pp.378~381 (2002)
  109. Tava F, "Type or extension of intestinal metaplasia and immature", atypical “indefinite-fordysplasia” lesions as predictors of gastric neoplasia, 2006, pp.37, 1489~1497
  110. Busuttil RA, "Intestinal metaplasia: a premalignant lesion involved in gastric carcinogenesis", J Gastroenterol Hepatol, 24, pp.193~201 (2009)
  111. Areia M, "Screening for gastric cancer and surveillance of premalignant lesions: a systematic review of cost-effectiveness studies", Helicobacter, 18, pp.325~337 (2013)

이 간행물의 다른 논문 (17건)

The Elderly Also Deserves to Undergo Therapeutic Endoscopy Safely under Sedation with Propofol by Gastroenterologists김상균pp. 1-2Benign Colorectal Stricture: An Answer to the Balloon or Stent Question?이호수, 변정식pp. 3-4Current and Emerging Biologics for Ulcerative Colitis박성철, 진윤태pp. 18-27Celiac Disease: A Disorder Emerging from Antiquity, Its Evolving Classification and Risk, and Potential New Treatment ParadigmsHugh J. Freemanpp. 28-37Safety of Gastroenterologist-Guided Sedation with Propofol for Upper Gastrointestinal Therapeutic Endoscopy in Elderly Patients Compared with Younger PatientsChika Kusano, Masakatsu Fukuzawa, Fuminori Moriyasu, Takao Itoi, Takuji Gotoda, Masaya Nonakapp. 38-42
원문 보기